Loading...
XASX
NEU
Market cap1.01bUSD
May 02, Last price  
12.44AUD
1D
5.42%
1Q
-14.15%
Jan 2017
972.41%
IPO
99.12%
Name

Neuren Pharmaceuticals Ltd

Chart & Performance

D1W1MN
XASX:NEU chart
No data to show
P/E
11.01
P/S
7.21
EPS
1.13
Div Yield, %
—
Shrs. gr., 5y
5.48%
Rev. gr., 5y
237.52%
Revenues
217m
-6.51%
429,665172,967944,1602,274,3625,003,2374,648,090004,794,0002,931,0001,673,0003,150,000631,00013,990,000495,000717,0003,197,00014,553,000231,925,000216,832,000
Net income
142m
-9.57%
000099,5620000-8,297,000-13,397,000-12,014,0003,288,0003,073,000-10,816,000-9,193,000-7,794,000184,000157,081,000142,043,000
CFO
-11m
L
000000000-6,410,000-12,731,000-12,378,000-5,590,0006,408,000-11,719,000-8,077,999-9,970,0003,599,000184,925,000-11,270,000
Earnings
May 28, 2025

Profile

Neuren Pharmaceuticals Limited, a biopharmaceutical company, develops drugs for the treatment of neurological disorders. Its lead product is trofinetide, which is in Phase III clinical trial for the treatment of Rett syndrome, as well as has completed Phase II clinical trial to treat Fragile X syndrome. The company also develops NNZ-2591, which has completed Phase I clinical trial for the treatment of Phelan-McDermid, Angelman, Pitt Hopkins, and Prader-Will syndromes. In addition, it provides development services; and holds loan funded shares. The company was incorporated in 2001 and is based in Camberwell, Australia.
URL
https://www.neurenpharma.com/
IPO date
Feb 03, 2005
Employees
Domiciled in
AU
Incorporated in
NZ

Valuation

Title
AUD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
216,832
-6.51%
231,925
1,493.66%
14,553
355.21%
Cost of revenue
70,641
59,448
16,149
Unusual Expense (Income)
NOPBT
146,191
172,477
(1,596)
NOPBT Margin
67.42%
74.37%
Operating Taxes
40,897
48,059
(864)
Tax Rate
27.98%
27.86%
NOPAT
105,294
124,418
(732)
Net income
142,043
-9.57%
157,081
85,270.11%
184
-102.36%
Dividends
Dividend yield
Proceeds from repurchase of equity
(8,766)
3,619
(4)
BB yield
0.54%
-0.11%
0.00%
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
41
Net debt
(222,242)
(228,539)
(40,180)
Cash flow
Cash from operating activities
(11,270)
184,925
3,599
CAPEX
(10)
(40)
(19)
Cash from investing activities
4,134
(211,485)
(19)
Cash from financing activities
(8,775)
3,619
(2)
FCF
(13,045)
112,811
329
Balance
Cash
222,242
228,539
40,180
Long term investments
Excess cash
211,400
216,943
39,452
Stockholders' equity
363,904
205,207
41,589
Invested Capital
152,545
2,137
ROIC
69.03%
ROCE
40.17%
84.05%
EV
Common stock shares outstanding
130,780
130,768
128,909
Price
12.50
-49.94%
24.97
214.09%
7.95
110.88%
Market cap
1,634,745
-49.94%
3,265,289
218.62%
1,024,827
130.82%
EV
1,412,503
3,036,750
984,647
EBITDA
146,191
172,494
(1,586)
EV/EBITDA
9.66
17.60
Interest
Interest/NOPBT